imdevimab   Click here for help

GtoPdb Ligand ID: 11328

Synonyms: REGN-10987 | REGN10987 | Ronapreve® (imdevimab + casirivimab)
Approved drug
imdevimab is an approved drug (Japan, EMA and UK MHRA (2021))
Compound class: Antibody
Comment: Imdevimab is a fully human monoclonal antibody against the surface spike protein of SARS-CoV-2 [1-2]. It is a virus neutralising mAb that was developed by Regeneron.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CoV Spike glycoprotein SARS-CoV-2 Antibody Binding 9.6 pIC50 - 2
⤷ pIC50 9.6 (IC50 2.3x10-10 M) [2]
Description: IC50 for ability of mAb to compete with spike protein for binding to hACE2.